ALFA FinderNSE filing, NSE: REMUS. Summary written from the filing by ALFA Finder's alert engine.
Remus Pharmaceuticals Ltd: key numbers
- Share price
- ₹800.45
- Market cap
- ₹943.2 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 25.5×Sector 43.0×
- Promoter holding
- 70.95%
- FII holding
- 5.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Remus Pharmaceuticals Ltd
All →Remus Pharmaceuticals Earnings Call Transcript: Key Takeaways
Remus delivered strong H1 growth led by international operations, though consolidated margins are skewed by a low-margin US distribution transaction.
Remus Pharmaceuticals Investor Presentation: Key Takeaways
H1-FY27 consolidated revenue INR 6,141 Mn (+53.4%) and PAT INR 247 Mn (+14.4%), with EBITDA margin compressing to 4.87%. Standalone PAT rose 56.7%. Growth comes from tender wins and LATAM/SEA expansion.
Remus Pharmaceuticals Results Update
Remus Pharmaceuticals reported H1 FY27 results with standalone revenue of ₹62.08 Cr (up 32.51%) and consolidated revenue of ₹614.12 Cr (up 53.45%). The media release also highlights new tenders, approvals and portfolio expansion across international markets.
Remus Pharmaceuticals Dividend
Remus Pharmaceuticals has fixed 7 November 2026 as the record date for its 1st interim dividend for FY 2026-27, declared at today's board meeting. The filing does not state the per-share dividend amount.
Remus Pharmaceuticals H1 FY27 Results: Net Profit ₹24.7 Cr, Up 14.4% YoY
Remus Pharmaceuticals Ltd reported revenue from operations of ₹614.1 Cr (+53.4% YoY) and net profit of ₹24.7 Cr (+14.4% YoY) for H1 FY27.
- Key figure
- Net profit ₹24.7 Cr · +14.4% YoY
Remus Pharmaceuticals Other Announcement
Remus Pharmaceuticals filed its Reg 76 Reconciliation of Share Capital Audit Report for Q1 FY2027. It is a routine depository-compliance certificate with no transaction or business event.
Other board meeting date announcements
All →Hasti Finance Board Meeting Date
Hasti Finance Limited will hold a board meeting on 14 November 2026 to consider unaudited financial results for the quarter and half year ended 30 September 2026. The trading window stays closed until 48 hours after the results are declared.
Neelam Linens And Garments (India) Board Meeting Date
Neelam Linens and Garments (India) Limited will hold a board meeting on 14 November 2026 to consider unaudited standalone half-yearly results for September 2026. The trading window stays closed until 16 November 2026.
Ultra Wiring Connectivity Systems Board Meeting Date
Ultra Wiring Connectivity will hold a board meeting on 14 Nov 2026 to consider unaudited half-yearly results. Trading window stays closed until 17 Nov 2026.
Roopa Industries Board Meeting Date
Roopa Industries Ltd intimated a board meeting on 14 Nov 2026 to consider unaudited half-year and quarterly results ended 30 Sep 2026. Trading window stays closed until 48 hours after results are made public.
Uravi Defence and Technology Board Meeting Date
Uravi Defence schedules a board meeting on 14 November 2026 to approve September quarter and half-year results. Trading window remains closed until 48 hours post-results.
Soma Textiles & Industries Board Meeting Date
Soma Textiles will hold a board meeting on 11 November 2026 to consider quarterly results for September 2026. The trading window remains closed until 13 November 2026.